Furthermore, in melanoma patients, serum IL8 levels were found to be linked with tumor size and stage, survival rates, and measurable treatment responses, including responses to BRAF inhibitors and immune-targeting monoclonal antibodies [71]. Here, CXCL8 is linked to neoplasm.